Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells

Psychopharmacology

Volumn 124, Issue 1-2, 1996, Pages 50-56

  Stockton, Marsha E ^a   Rasmussen, Kurt ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Atypical antipsychotic; Clozapine; d Amphetamine; Dopamine; Electrophysiology; Olanzapine; Schizophrenia

Indexed keywords

CLOZAPINE; DEXAMPHETAMINE; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE UNIT ACTIVITY; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DOPAMINE AGENTS; ELECTROPHYSIOLOGY; MALE; MESENCEPHALON; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030012214     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02245605     Document Type: Article

References (54)

1. Beasley CM, Tollefson GD, Sanger T, Tran P, Holman S, and the North American Olanzapine Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:105-118
2. Benvenga MJ, Leander JD (1995) Olanzapine, and atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 119:133-138
3. Bernardini GL, Gu X, Viscardi E, German DC (1991) Amphetamine-induced and spontaneous release of dopamine from A9 and A10 cell dendrites: an in vitro electrophysiological study in the mouse. J Neural Transm 84:183-193
4. Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15:24S-29S
5. Bowery B, Rothwell LA, Seabrook GR (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental atea. Br J Pharmacol 112:873-880
6. Bunney BS (1977) Central dopaminergic systems: two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic drugs. In: Hanin I, Usdin E (eds) Animal models in psychiatry and neurology. Pergamon Press, New York, pp 91-104
7. Bunney BS, Aghajanian GK (1973) Electrophysiological effects of amphetamine on dopaminergic neurons. In: Snyder S, Usdin E (eds) Frontiers in catecholamine research. Pergamon Press, New York, pp 957-962
8. Bunney BS, Aghajanian GK (1974) A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopaminergic neurons. Life Sci 15:309-318
9. Bunney BS, Aghajanian GK (1975) Antipsychotic drugs and central dopaminergic neurons, a model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In: Sudilovsky A, Gershon S, Beer B (eds) Predictability in psychopharmacology: preclinical and clinical correlations. Raven Press, New York, pp 225-245
10. Bunney BS, Aghajanian GK (1976) The effect of antipsychotic drugs on the firing of dopaminergic neurons: a reappraisal. In: Sedvall G, Uvnas B, Zotterman Y (eds) Antipsychotic drugs: pharmacodynamics and pharmakokinetics. Pergamon Press, New York, pp 305-318
11. Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560-571
12. Bymaster FP, Colligaro DO, Falcone JF, Marsh RD, Moore ND, Tye NC, Seeman P, Wong DT (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
13. Bymaster FP, Perry KW, Hemrick-Luecke SK, Fuller RW (1996b) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin alpha 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94
14. Carlsson A, Lindqvest M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140-144
15. Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 3:1607-1619
16. Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS (1984) Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of midbrain dopamine neurons. Neuroscience 12:1-16
17. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbock R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus clorpromazine. J Psychopharmacol 7:377-384
18. Connell PA (1958) Amphetamine psychosis. Maudsley Monograph no 5. Oxford University Press, London
19. Corrodi H, Fuxe K, Hokfelt T (1967) The effect of some psychoactive drugs on central monoamine neurons. Eur J Pharmacol 1:363-368
20. Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia, a review and reconceptualization. Am J Psychiatry 148:1474-1486
21. De la Chapelle A, Kari C, Nurminen M, Hernberg S (1977) Clozapine-induced agranulocytosis. Hum Genet 37:183-194
22. Deutch AY (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm [GenSect ]91:197-221
23. Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY 170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87-93
24. 2 receptor blockade on amphetamine (AMP) inhibition of dopamine (DA) cell firing. Fed Proc 45:436
25. 2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249 [no 3]:673-679
26. Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293-298
27. Grace AA (1991) Phasic versus tonic release and the modulation of dopamine system responsivity, a hypothesis for the etiology of schizophrenia. Neuroscience 41:1-24
28. Grace AA, Bunney BS (1979) Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticular inhibitory neurons. Eur J Pharmacol 59:211-218
29. Griffith JJ, Oates J, Cavanaugh J (1968) Paranoid episodes induced by drugs. JAMA 205:39
30. Griffith RW, Saameli K (1975) Clozapine and agranulocytosis. Lancet 2:657
31. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702-712
32. Juul Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176-185
33. Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
34. Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz DL, Howard A (1988) Clozapine induced agranulocytosis: non-cross reactivity with psychotropic drugs. J Clin Psychiatry 49:271-277
35. Losonczy MF, Davidson M, Davis KL (1987) The dopamine hypothesis of schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 715-726
36. Meador-Woodruff JH, Damask SP, Watson SJ (1994) Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 91:8287-8301
37. Meltzer HY, Bastani B, Kwon B, Ramirez L, Burnett S, Shapre J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99 [Suppl]:S68-S72
38. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994) Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comp Psychiatry 35:8-15
39. Moore NA, Tye NC, Axton MS, Risius F (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
40. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (in press)
41. O'Brien DP, White FJ (1987) Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity. Eur J Pharmacol 142:343-354
42. Pucak ML, Grace AA (1994) Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271:1181-1192
43. 3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 205:113-116
44. SancheZ C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, Perregaard J, Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239-250
45. Serby M, Angrist B, Leiberman A (1978) Mental disturbance during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry 135:1227-1229
46. Shepard PD, German DC (1984) A subpopulation of mesocortical dopamine neurons possess autoreceplors. Eur J Pharmacol 114:401-402
47. Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 10:25-33
48. Spensley J, Rockwell DA (1972) Psychosis during methyl-phenidate abuse. N Engl J Med 286:880-881
49. Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97-104
50. Wang RY (1981) Dopaminergic neurons in the rat vemtral tegmental area. III. Effects of d- and l-amphetamiinie. Brain Res Rev 3:153-165
51. Waszczak BL, Bergstrom DA, Walters JR (1981) Single unit responses of substantia nigra and globus pallidus neurons to GABA agonist and antagonist drugs. In: Di Chiara G, Gessa GL (eds) GABA and the basal ganglia. Raven Press, New York, pp 79-94
52. White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054-1057
53. White EJ, Wang RX (1984) A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity do dopamine agonists. Life Sci 34:1161-1170
54. Young D, Scoville WB (1938) Paranoid psychosis in narcolepsy and the possible dangers of benzedrine treatment. Med Clin N Am 22:637-646